Article: Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus
| Title | Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors | Fang, Y1 3 5 Rowe, T1 3 Leon, AJ3 Banner, D1 Danesh, A1 5 Xu, L1 Ran, L1 Bosinger, SE4 Guan, Y3 Chen, H3 Cameron, CC1 Cameron, MJ1 Kelvin, DJ1 2 3 5 | ||||||||||
| Issue Date | 2010 | ||||||||||
| Publisher | American Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/ | ||||||||||
| Citation | Journal Of Virology, 2010, v. 84 n. 17, p. 8369-8388 [How to Cite?] DOI: http://dx.doi.org/10.1128/JVI.02305-09 | ||||||||||
| Abstract | The 2009 H1N1 influenza pandemic has prompted a significant need for the development of efficient, single-dose, adjuvanted vaccines. Here we investigated the adjuvant potential of CpG oligodeoxynucleotide (ODN) when used with a human seasonal influenza virus vaccine in ferrets. We found that the CpG ODNadjuvanted vaccine effectively increased antibody production and activated type I interferon (IFN) responses compared to vaccine alone. Based on these findings, pegylated IFN-α2b (PEG-IFN) was also evaluated as an adjuvant in comparison to CpG ODN and complete Freund's adjuvant (CFA). Our results showed that all three vaccines with adjuvant added prevented seasonal human A/Brisbane/59/2007 (H1N1) virus replication more effectively than did vaccine alone. Gene expression profiles indicated that, as well as upregulating IFN-stimulated genes (ISGs), CpG ODN enhanced B-cell activation and increased Toll-like receptor 4 (TLR4) and IFN regulatory factor 4 (IRF4) expression, whereas PEG-IFN augmented adaptive immunity by inducing major histocompatibility complex (MHC) transcription and Ras signaling. In contrast, the use of CFA as an adjuvant induced limited ISG expression but increased the transcription of MHC, cell adhesion molecules, and B-cell activation markers. Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvant-mediated influenza virus vaccinations. Copyright © 2010, American Society for Microbiology. All Rights Reserved. | ||||||||||
| ISSN | 0022-538X 2011 Impact Factor: 5.402 2011 SCImago Journal Rankings: 0.745 | ||||||||||
| DOI | http://dx.doi.org/10.1128/JVI.02305-09 | ||||||||||
| ISI Accession Number ID | WOS:000280605300002
Funding Information: This work is supported by grants from the Li Ka Shing Foundation, the Canadian Institute of Health Research, Sardegna Ricerche, and the National Institutes of Health. | ||||||||||
| PubMed Central ID | PMC2919000 | ||||||||||
| References | References in Scopus |
| dc.contributor.author | Fang, Y | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| dc.contributor.author | Rowe, T | ||||||||||
| dc.contributor.author | Leon, AJ | ||||||||||
| dc.contributor.author | Banner, D | ||||||||||
| dc.contributor.author | Danesh, A | ||||||||||
| dc.contributor.author | Xu, L | ||||||||||
| dc.contributor.author | Ran, L | ||||||||||
| dc.contributor.author | Bosinger, SE | ||||||||||
| dc.contributor.author | Guan, Y | ||||||||||
| dc.contributor.author | Chen, H | ||||||||||
| dc.contributor.author | Cameron, CC | ||||||||||
| dc.contributor.author | Cameron, MJ | ||||||||||
| dc.contributor.author | Kelvin, DJ | ||||||||||
| dc.date.accessioned | 2010-10-31T11:14:14Z | ||||||||||
| dc.date.available | 2010-10-31T11:14:14Z | ||||||||||
| dc.date.issued | 2010 | ||||||||||
| dc.description.abstract | The 2009 H1N1 influenza pandemic has prompted a significant need for the development of efficient, single-dose, adjuvanted vaccines. Here we investigated the adjuvant potential of CpG oligodeoxynucleotide (ODN) when used with a human seasonal influenza virus vaccine in ferrets. We found that the CpG ODNadjuvanted vaccine effectively increased antibody production and activated type I interferon (IFN) responses compared to vaccine alone. Based on these findings, pegylated IFN-α2b (PEG-IFN) was also evaluated as an adjuvant in comparison to CpG ODN and complete Freund's adjuvant (CFA). Our results showed that all three vaccines with adjuvant added prevented seasonal human A/Brisbane/59/2007 (H1N1) virus replication more effectively than did vaccine alone. Gene expression profiles indicated that, as well as upregulating IFN-stimulated genes (ISGs), CpG ODN enhanced B-cell activation and increased Toll-like receptor 4 (TLR4) and IFN regulatory factor 4 (IRF4) expression, whereas PEG-IFN augmented adaptive immunity by inducing major histocompatibility complex (MHC) transcription and Ras signaling. In contrast, the use of CFA as an adjuvant induced limited ISG expression but increased the transcription of MHC, cell adhesion molecules, and B-cell activation markers. Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvant-mediated influenza virus vaccinations. Copyright © 2010, American Society for Microbiology. All Rights Reserved. | ||||||||||
| dc.description.nature | link_to_OA_fulltext | ||||||||||
| dc.identifier.citation | Journal Of Virology, 2010, v. 84 n. 17, p. 8369-8388 [How to Cite?] DOI: http://dx.doi.org/10.1128/JVI.02305-09 | ||||||||||
| dc.identifier.doi | http://dx.doi.org/10.1128/JVI.02305-09 | ||||||||||
| dc.identifier.epage | 8388 | ||||||||||
| dc.identifier.hkuros | 180506 | ||||||||||
| dc.identifier.isi | WOS:000280605300002
Funding Information: This work is supported by grants from the Li Ka Shing Foundation, the Canadian Institute of Health Research, Sardegna Ricerche, and the National Institutes of Health. | ||||||||||
| dc.identifier.issn | 0022-538X 2011 Impact Factor: 5.402 2011 SCImago Journal Rankings: 0.745 | ||||||||||
| dc.identifier.issue | 17 | ||||||||||
| dc.identifier.openurl | ![]() | ||||||||||
| dc.identifier.pmcid | PMC2919000 | ||||||||||
| dc.identifier.pmid | 20534862 | ||||||||||
| dc.identifier.scopus | eid_2-s2.0-77956642388 | ||||||||||
| dc.identifier.spage | 8369 | ||||||||||
| dc.identifier.uri | http://hdl.handle.net/10722/125150 | ||||||||||
| dc.identifier.volume | 84 | ||||||||||
| dc.language | eng | ||||||||||
| dc.publisher | American Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/ | ||||||||||
| dc.publisher.place | United States | ||||||||||
| dc.relation.ispartof | Journal of Virology | ||||||||||
| dc.relation.references | References in Scopus | ||||||||||
| dc.rights | Journal of Virology. Copyright © American Society for Microbiology. | ||||||||||
| dc.rights | Copyright © American Society for Microbiology, Journal of Virology, 2010, v. 84 n. 17, p. 8369-8688 | ||||||||||
| dc.subject.mesh | Ferrets | ||||||||||
| dc.subject.mesh | Influenza A Virus, H1N1 Subtype - genetics - immunology - physiology | ||||||||||
| dc.subject.mesh | Influenza Vaccines - administration and dosage - genetics - immunology | ||||||||||
| dc.subject.mesh | Influenza, Human - immunology - prevention and control - virology | ||||||||||
| dc.subject.mesh | Oligodeoxyribonucleotides - administration and dosage - immunology | ||||||||||
| dc.title | Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus | ||||||||||
| dc.type | Article |
Author Affiliations
- Toronto General Research Institute
- Università degli Studi di Sassari
- Shantou University, Medical College (SUMC)
- University of Pennsylvania
- University of Toronto


